340 related articles for article (PubMed ID: 34274492)
61. Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients.
Hoffman TW; Meek B; Rijkers GT; van Kessel DA
Transpl Immunol; 2022 Jun; 72():101599. PubMed ID: 35390480
[TBL] [Abstract][Full Text] [Related]
62. A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients.
Watanabe M; Yakushijin K; Funakoshi Y; Ohji G; Ichikawa H; Sakai H; Hojo W; Saeki M; Hirakawa Y; Matsumoto S; Sakai R; Nagao S; Kitao A; Miyata Y; Koyama T; Saito Y; Kawamoto S; Yamamoto K; Ito M; Murayama T; Matsuoka H; Minami H
Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366338
[TBL] [Abstract][Full Text] [Related]
63. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
64. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
65. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
Citu IM; Citu C; Gorun F; Sas I; Tomescu L; Neamtu R; Motoc A; Gorun OM; Burlea B; Bratosin F; Malita D
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215900
[TBL] [Abstract][Full Text] [Related]
66. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.
Kitagawa H; Kaiki Y; Sugiyama A; Nagashima S; Kurisu A; Nomura T; Omori K; Akita T; Shigemoto N; Tanaka J; Ohge H
J Infect Chemother; 2022 Apr; 28(4):576-581. PubMed ID: 35058126
[TBL] [Abstract][Full Text] [Related]
67. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
Farina A; Falso S; Cornacchini S; Spagni G; Monte G; Mariottini A; Massacesi L; Barilaro A; Evoli A; Damato V
Eur J Neurol; 2022 Aug; 29(8):2505-2510. PubMed ID: 35390184
[TBL] [Abstract][Full Text] [Related]
68. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
69. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
[TBL] [Abstract][Full Text] [Related]
70. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
71. mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
Barzen G; Rieber F; Stangl K; Hahn K; Spethmann S
Vaccine; 2024 Feb; 42(4):723-726. PubMed ID: 38158299
[TBL] [Abstract][Full Text] [Related]
72. Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.
Alhashim A; Hadhiah K; Al Khalifah Z; Alhaddad FM; Al ARhain SA; Bin Saif FH; Abid A; Al Gamdi O; Alsulaiman F; AlQarni M
Am J Case Rep; 2022 Feb; 23():e934744. PubMed ID: 35136010
[TBL] [Abstract][Full Text] [Related]
73. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.
Pawlowski C; Lenehan P; Puranik A; Agarwal V; Venkatakrishnan AJ; Niesen MJM; O'Horo JC; Virk A; Swift MD; Badley AD; Halamka J; Soundararajan V
Med; 2021 Aug; 2(8):979-992.e8. PubMed ID: 34223401
[TBL] [Abstract][Full Text] [Related]
74. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
[TBL] [Abstract][Full Text] [Related]
75. Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years.
Toepfner N; von Meißner WCG; Strumann C; Drinka D; Stuppe D; Jorczyk M; Moor J; Püschel J; Liss M; von Poblotzki E; Berner R; Moor MB; Chao CM
JAMA Netw Open; 2022 Oct; 5(10):e2237140. PubMed ID: 36255723
[TBL] [Abstract][Full Text] [Related]
76. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Immunol; 2022; 13():956825. PubMed ID: 36177033
[TBL] [Abstract][Full Text] [Related]
77. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
78. Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients.
Chiarucci M; Paolasini S; Isidori A; Guiducci B; Loscocco F; Capalbo M; Visani G
Front Oncol; 2021; 11():737300. PubMed ID: 34552880
[TBL] [Abstract][Full Text] [Related]
79. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
[TBL] [Abstract][Full Text] [Related]
80. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
Khehra N; Padda I; Jaferi U; Atwal H; Narain S; Parmar MS
AAPS PharmSciTech; 2021 Jun; 22(5):172. PubMed ID: 34100150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
